Restless leg syndrome (RLS) is a neurological disorder. The National Institute of Neurological Disorders and Stroke classifies it as a neurological condition that causes an irresistible urge to move the legs. It also falls under two additional categories: a sleep disorder, because symptoms are triggered by resting and attempting to sleep, and a movement disorder, because people with RLS are forced to move their legs to find relief. This triple classification reflects how deeply the condition is rooted in nervous system dysfunction rather than being a muscular or psychological problem.
An estimated 7.1% of adults worldwide have RLS, which translates to roughly 356 million people between the ages of 20 and 79. The severity varies widely, and many people with mild symptoms never seek treatment, which means the condition is both common and significantly underdiagnosed.
What Happens in the Brain
The neurological basis of RLS centers on two interconnected problems: disrupted dopamine signaling and insufficient iron levels in the brain.
Dopamine is the chemical messenger your nervous system uses to regulate movement, sensory perception, and pain processing. In RLS, dopamine signaling between nerve cells is decreased on the receiving end, even though the brain may actually be producing more dopamine than normal. This paradox, where production goes up but the signal still doesn’t get through properly, helps explain why the condition is so difficult to treat. The area most affected is a deep brain structure called the basal ganglia, which acts as a gatekeeper between pain signals and the parts of the brain that control movement. When dopamine signaling breaks down there, uncomfortable sensations leak through and trigger the urge to move.
Iron plays a critical role because brain cells need it to produce and regulate dopamine. MRI scans and autopsy studies from Johns Hopkins have shown that people with RLS have insufficient iron in their brain tissue. The problem isn’t necessarily a lack of iron in the bloodstream. Instead, brain cells appear to have a decreased ability to absorb the iron that’s available to them. Researchers believe this is a functional defect rather than a structural one, meaning the cellular machinery is intact but not working correctly. That distinction is important because it suggests effective treatment is possible.
Primary vs. Secondary RLS
RLS comes in two forms. Primary RLS has no identifiable outside cause and tends to run in families. It usually starts before age 40 and worsens gradually over a lifetime. Secondary RLS is triggered or worsened by another medical condition, and treating that underlying condition can sometimes resolve symptoms entirely.
The most common triggers of secondary RLS include:
- Iron deficiency: Low iron stores from heavy menstrual periods, frequent blood donation, or gastrointestinal bleeding can cause or worsen RLS directly.
- Kidney failure: When kidneys stop functioning properly, iron stores in the blood drop and body chemistry shifts in ways that provoke RLS symptoms.
- Peripheral neuropathy: Nerve damage in the hands and feet, often from diabetes or alcohol use disorder, is linked to RLS.
- Pregnancy: Hormonal changes can trigger RLS for the first time, especially in the third trimester. Symptoms typically disappear after delivery.
- Spinal cord conditions: Damage or injury to the spinal cord has been associated with RLS onset.
- Parkinson’s disease: People with Parkinson’s have an increased risk of developing RLS, likely because both conditions involve dopamine dysfunction.
How Symptoms Present
RLS produces unusual sensations deep inside the legs, most often described as crawling, pulling, throbbing, or an ache that doesn’t quite fit any normal category. These sensations are distinct from muscle cramps or numbness. They create a nearly uncontrollable need to move, and moving temporarily relieves the discomfort. The pattern is predictable: symptoms appear or worsen during periods of rest, particularly in the evening and at night, and improve with activity.
For many people, the sleep disruption is the most damaging aspect. Because symptoms intensify when you’re trying to fall asleep, RLS can dramatically reduce sleep quality and lead to daytime exhaustion, difficulty concentrating, and mood changes that compound over months and years.
How Treatment Has Changed
Treatment for RLS has shifted significantly in the past few years. Dopamine-boosting medications were the gold standard for over a decade, but clinical guidelines published in 2024 by the American Academy of Sleep Medicine now conditionally recommend against them. The reason: long-term use causes a problem called augmentation, where the medication gradually makes symptoms worse instead of better. Augmentation rates turned out to be high enough that the risks outweigh the benefits for most patients.
The current first-line treatments are gabapentin, pregabalin, and gabapentin enacarbil. These medications work by calming overactive nerve signaling rather than boosting dopamine. They’ve shown strong efficacy in clinical trials, though they can cause sedation, dizziness, and weight gain. Only gabapentin enacarbil currently has FDA approval specifically for RLS.
Iron evaluation is now considered essential for everyone diagnosed with RLS. Updated guidelines emphasize that iron levels in people with RLS often need to be higher than what’s considered normal for the general population. Regular monitoring of iron levels is recommended, and intravenous iron supplementation is one of four strongly recommended treatments. For people whose RLS is driven by low brain iron, correcting that deficiency can produce substantial improvement without the side effects of daily medication.
For cases that don’t respond to first-line options, certain opioid formulations and a nerve stimulation device targeting the lower leg are conditionally recommended. Older sedative medications like clonazepam, once commonly prescribed, are now recommended against due to risks of excessive sedation and cognitive impairment.
Why the Neurological Label Matters
Understanding that RLS is a neurological disorder, not a habit, anxiety symptom, or minor nuisance, changes how it gets taken seriously by both patients and clinicians. People with RLS have measurable differences in brain iron metabolism and dopamine function. These are not subjective complaints or signs of restlessness. They reflect a specific pattern of nervous system dysfunction that can be identified through imaging and blood work and targeted with treatment. If your symptoms are disrupting your sleep or daily functioning, that context can help you advocate for appropriate evaluation, starting with iron studies and a conversation about the current treatment options rather than older medications that may do more harm than good.